1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
2. U.S. Preventive Services Task Force. Screening for gestational diabetes mellitus: recommendations and rationale. Obstet Gynecol 2003;101:393-5.
3. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ 2001;322:986-8.
4. Engelgau MM, Aubert RE, Thompson TJ, Herman WH. Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations. Diabetes Care 1995;18:1606-18.
5. Harris MI, Modan M. Screening for NIDDM. Why is there no national program? Diabetes Care 1994;17:440-4.
6. Marshall KG. The folly of population screening for type 2 diabetes. CMAJ. 1999;160:1592-3.
7. Goyder E, Irwig L. Screening for diabetes: what are we really doing? BMJ 1998;317:1644-6.
8. Davidson MB. The case for screening for type 2 diabetes in selected populations. BMJ USA 2001;1:297-8.
9. American Association of Clinical Endocrinologists. ACE consensus statement on guidelines for glycemic control. Endocr Pract 2002;8 (Suppl 1):5-11.
10. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000;23:1563-80.
11. American Diabetes Association. Screening for diabetes. Diabetes Care 2001;24:S21-S24.
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
15. Harris, R, Donahue, K, Rathore, S, Frame, P, Woolf, S, Lohr, KN. Screening for Type 2 Diabetes Mellitus. Systematic Evidence Review No. 19. Prepared by the RTI International Evidence-based Practice Center under Contract No. 290-97-0011. Rockville, MD: Agency for Healthcare Research and Quality. 2003. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat3.chapter.3895.
16. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63.
17. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
18. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23 Suppl 2:B54-B64.
19. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-1097.
20. Wingard DL, Barrett-Connor E. Heart Disease and diabetes. In: National Diabetes Data Group, ed. Diabetes in America. 2nd ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468; 1995.
21. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51.
22. Rolka DB, Narayan KM, Thompson TJ, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001;24:1899-1903.
23. 1999 Medicare Clinical Diagnostic Laboratory Fee Schedule. Baltimore, MD: Health Care Financing Administration; 1998.
24. Relative Value Studies I. Relative Values for Physicians. United States: St. Anthony's Publishing, Inc.; 1997.
25. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Med Decis Making 1985;5:157-77.
26. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127:788-95.
27. Hofer TP, Vijan S, Hayward RA. Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 2000;16:822-33.
28. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001;111:633-42.
29. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317:720-6.
30. Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Arch Intern Med 2000;160:1277-83.
31. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-80.
32. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25:476-541.
33. Goyder EC, Irwig LM. Screening for Type 2 diabetes mellitus: a decision analytic approach. Diabet Med 2000;17:469-77.
34. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
35. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
36. National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) III, Series 11, No. 1A. Available from: http://www.cdc.gov/nchs/about/major/nhanes/nh3data.htm. July 1997.
37. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: I. Model construction and assumptions. Diabetes Care 1997;20:725-34.
38. Dong F, Orians C, Manninen D. Economic Evaluation of Approaches to Preventing Diabetic End-Stage Renal Disease. Prepared for the Centers for Disease Control and Prevention. Seattle, Washington: Battelle-Centers for Public Health Research and Evaluation; 1997.
39. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409-15.
40. Humphrey LL, Ballard DJ, Frohnert PP, Chu C-P, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus. Ann Intern Med 1989;111:788-96.
41. Eckman MH, Greenfield C, Mackey WC, et al. Foot infections in diabetic patients. JAMA 1995;273:712-20.
42. Humphrey LL, Palumbo PJ, Butters MA, et al. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med 1994:154:885-92.
43. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In Diabetes in America, 2nd ed. National Diabetes Data Group, eds, 409-28. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
44. Moss SE, Klein R, Klein B. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-6.
45. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998;21:1122-8.
46. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol May 1998;1110-5.
47. Nease RF, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L. Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA 1995;273:1185-90.
48. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-5.
49. Wolf PA, D'Agostino RB, O'Neal A, et al. Secular trends in stroke incidence and mortality. Stroke 1992;23:1551-5.
50. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology 1994;44:626-34.
51. Taylor TN, Davis PH, Torner JC, Homes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-66.
52. Red Book. 1997 Drug Topics. Montvale, NJ: Medical Economics; 1997.
[a] Hoerger, Hicks: RTI International, Research Triangle Park, NC.
[b] Harris: The Cecil G. Sheps Center for Health Services
Research, Department of Medicine, University of North Carolina at Chapel Hill, Chapel
Hill, NC.
[c] Donahue: Department of Family Practice, University of North Carolina School of Medicine, Chapel Hill, NC.
[d] Sorenson, Engelgau: Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.
This document is in the public domain within the United States. For information on reprinting, contact Randie Siegel, Director, Division of Printing and Electronic Publishing, Agency for Healthcare Research and Quality, Suite 501, 2101 East Jefferson Street, Rockville MD, 20852.
Requests for linking or to incorporate content in electronic resources should be sent to: info@ahrq.gov.
Source: Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. May 2004. Originally in Ann Intern Med 2004;140:689-99.
Current as of May 2004
Internet Citation:
Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for Type 2 Diabetes: A Cost-effectiveness Analysis. May 2004. Originally in Ann Intern Med 2004;140:689-99. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/diabscr/diabcost.htm
Return to USPSTF Topic Index
U.S. Preventive Services Task Force (USPSTF)
Clinical Information
AHRQ Home Page